TD Cowen Reiterates Buy on Humacyte, Maintains $10 Price Target
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Joshua Jennings has reiterated a Buy rating on Humacyte (NASDAQ:HUMA) and maintained a $10 price target.
October 18, 2024 | 3:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TD Cowen analyst Joshua Jennings has reiterated a Buy rating on Humacyte and maintained a $10 price target, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $10 price target by TD Cowen suggests a positive outlook for Humacyte. This can lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100